The global antisense therapy market is supported by the growing need for treatments for rare genetic and neurological disorders. Approved antisense medicines for conditions such as spinal muscular atrophy and certain forms of amyotrophic lateral sclerosis demonstrate the clinical potential of this therapeutic approach. The antisense therapy market was valued at US$ 6.17 billion in 2025 and is...